Go Pro
TSE:BHC

Bausch Health Companies Q1 2026 Earnings Report

Bausch Health Companies logo
C$8.74 -0.29 (-3.21%)
As of 04:19 PM Eastern

Bausch Health Companies EPS Results

Actual EPS
C$1.08
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bausch Health Companies Revenue Results

Actual Revenue
$3.51 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bausch Health Companies Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Bausch Health Companies Earnings Headlines

Zacks Research Has Bearish Outlook for TSE:BHC Q3 Earnings
Brokers Set Expectations for TSE:BHC FY2026 Earnings
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Bausch Health (BHC) Q2 2026 Earnings Call Transcript
See More Bausch Health Companies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bausch Health Companies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bausch Health Companies and other key companies, straight to your email.

About Bausch Health Companies

Bausch Health Companies (TSE:BHC) (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.

View Bausch Health Companies Profile